Literature DB >> 27153263

Celltrion's infliximab copy shows path to biosimilars in US.

Eva von Schaper.   

Abstract

Mesh:

Substances:

Year:  2016        PMID: 27153263     DOI: 10.1038/nbt0516-454

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  2 in total

1.  Biosimilars or semi-similars?

Authors:  Huub Schellekens; Ellen Moors
Journal:  Nat Biotechnol       Date:  2015-01       Impact factor: 54.908

2.  First US biosimilar edges towards market.

Authors:  Melanie Senior
Journal:  Nat Biotechnol       Date:  2015-03       Impact factor: 54.908

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.